Organic nitrate-induced oxidant stress and cardiovascular therapy

Bibliography

• THADANI U: Secondary preventive potential of nitrates in ischaemic heart disease. Eur: Heart J. (1996) 17:F30–F36.
   Google Scholar
• THADANI U: Oral nitrates - more than symptomatic therapy in coronary artery disease? Cardiovasc. Drugs Ther. (1997) 11:213–218.
   Google Scholar
• SHILO L, HADARI R, KOVATZ S et al.: Appropriateness of nitrate use in a general medicine population. Ann. Pharmacother: (2001) 35:1339–1342.
   PubMedGoogle Scholar
• CHEN Z, ZHANG J, STAMLER JS: Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc. Nati Acad. Sci. (2002) 99:8306–8311.
   PubMed Web of Science ®Google Scholar
• •This paper proposes a leading candidate enzyme to account for therapeutically relevant GTN reductase activity.
   Google Scholar
• PARKERJD, FARRELL B, FENTON T et al.: Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation (1991) 84:2336–2345.
   PubMedGoogle Scholar
• MONZEL T, SAYEGH H, FREEMAN BA et al: Evidence for enhanced vascular superoxide anion production in nitrate tolerance.' Clin. Invest. (1995) 95:187–194.
   Google Scholar
• •This is a seminal report implicating oxidant stress in the development of clinically relevant nitrate tolerance.
   Google Scholar
• GORI T, PARKER JD: The puzzle of nitrate tolerance - pieces smaller than we thought? Circulation (2002) 106:2404–2408.
   PubMed Web of Science ®Google Scholar
• GORI T, PARKER JD: Nitrate tolerance - a unifying hypothesis. Circulation (2002) 106:2510–2513.
   PubMed Web of Science ®Google Scholar
• KURZ S, HINK U, NICKENIG G et al: Evidence for a causal role of the renin-angiotensin system in nitrate tolerance. Circulation (1999) 99:3181–3187.
   PubMedGoogle Scholar
• MCVEIGH GE, HAMILTON P, WILSON M et al.: Platelet nitric oxide and superoxide release during the development of nitrate tolerance - effect of supplemental ascorbate. Circulation (2002) 106:208–213.
   PubMed Web of Science ®Google Scholar
• GRYGLEWSKI RJ, PALMER RMJ, MONCADA S: Superoxide anion is involved in the breakdown of endothelium-derived relaxing factor. Nature (1986) 320:454–458.
   PubMed Web of Science ®Google Scholar
• MCGRATH LT, DIXON L, MORGAN DR et al.: Production of 8-Epi prostaglandin F20, in human platelets during administration of organic nitrates. " Am. Coll Cardiol. (2002) 40:820–825.
   Google Scholar
• CSONT T, CSONKA C, ONODY A et al: Nitrate tolerance does not increase production of peroxynitrite in the heart. Am. J. Physiol (2002) 283:H69–H76.
   Google Scholar
• JURT U, GORI T, RAVANDI A et al: Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid perwddation - a human in vivo study. J. Am. Coll Cardiol (2001) 38:854–859.
   PubMed Web of Science ®Google Scholar
• DIKALOV S, FINK B, SKATCHKOV M et al.: Comparison of glyceryl trinitrate-induced with pentaerythrityl tetranitrate-induced in vivo formation of superoxide radicals - effect of vitamin C. Free Rad. Biol. Med. (1999) 27:170–176.
   PubMedGoogle Scholar
• MONZEL T, HARRISON DG: Evidence for a role of oxygen-derived free radicals and protein kinase C in nitrate tolerance. J. Md. Med. (1997) 75:891–900.
   Google Scholar
• MONZEL T, GIAID A, KURZ S et al: Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc. Natl. Acad. Sci (1995) 92:5244–5248.
   PubMedGoogle Scholar
• WATANABE H, KAKIHANA M, OHTSUKA S et al.: Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance. Circulation (1997) 96:2545–2550.
   PubMed Web of Science ®Google Scholar
• WATANABE H, KAKIHANA M, SADANORI 0 et al.: Randomized, double-blind, placebo-controlled study of ascorbate on the preventative effect of nitrate tolerance in patients with congestive heart failure. Circulation (1998) 97:886–891.
   Google Scholar
• PACKER M, LEE WH, KESSLER PD et al.:Prevention and reversal of nitrate tolerance in patients with congestive heart failure. Engl. J. Med. (1987) 317:799–804.
   PubMed Web of Science ®Google Scholar
• BASSENGE E, FINK N, SKATCHKOV M et al: Dietary supplement with vitamin C prevents nitrate tolerance. J. Clin. Invest. (1998) 102:67–71.
   PubMed Web of Science ®Google Scholar
• ELKAYAM U, JOHNSON JV, SHOTAN A et al: Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with chronic heart failure treated with ACE inhibition. Circulation (1999) 99:2652–2657.
   PubMed Web of Science ®Google Scholar
• MEHRA A, OSTRZEGA E, SHOTAN A et al.: Persistent hemodynamic improvement with short-term nitrate therapy in patients with chronic congestive heart failure already treated with captopril. Am. J. Cardiol. (1992) 70:1310–1314.
   PubMed Web of Science ®Google Scholar
• GOGIA H, MEHRA A, PARIKH S et al.: Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J. Am. Coll. Cardiol. (1995) 26:1575–1580.
   PubMed Web of Science ®Google Scholar
• MONZEL T, KURZ S, RAJAGOPALAN S et al: Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH wddase. Clin. Invest. (1996) 98:1465–1470.
   Google Scholar
• BERKENBOOM G, FONTAINE D, UNGER P et al.: Absence of nitrate tolerance after long-term treatment with ramipril - an endothelium-dependent mechanism.Cardiovasc. Pharmacol (1999) 34:547–553.
   PubMedGoogle Scholar
• FINK B, SCHWEMMER M, BASSENGE E: Tolerance to nitrates with enhanced radical formation suppressed by carvedilol. j Cardiovasc. Pharmacol (1999) 34:800–805.
   PubMedGoogle Scholar
• ZIERHUT W, BALL HA: Prevention of vascular nitroglycerin tolerance by inhibition of protein kinase C. Br. j Pharmacol (1996) 119:3–5.
   PubMedGoogle Scholar
• KAESEMEYER WH, ABOU-MOHAMED G, CRUTE TD et al: Nitrates supplemented with L-arginine for the reversal and treatment of nitrate tolerance - two case reports. App. Cardiopulmon. Pathophysiol (1997) 6:255–262.
   Google Scholar
• GORI T, BURSTEIN JM, AHMED S et al.: Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance - a human in vivo study. Circulation (2001) 104:1119–1123.
   PubMed Web of Science ®Google Scholar
• MILONE SD, PACE-ASCIAK CR, REYNAUD D et al.: Biochemical, hemodynamic, and vascular evidence concerning the free radical hypothesis of nitrate tolerance. " Cardiovasc. Pharmacol (1999) 33:685–690.
   Google Scholar
• MILONE SD, AZEVEDO ER, FORSTER C et al: The angiotensin II-receptor antagonist losartan does not prevent hemodynamic or vascular tolerance to nitroglycerin.j Cardiovasc Pharmacol. (1999) 34:645–650.
   PubMedGoogle Scholar
• KEIMER R, STUTZER FK, TSIKAS D et al: Lack of oxidative stress during sustained therapy with isosorbide dinitrate and pentaerythrityl tetranitrate in healthy humans - a randomised, double-blind crossover study. Cardiovasc. Pharmacol (2003) 41:284–292.
   PubMed Web of Science ®Google Scholar
• WARNHOLTZ A, TSILIMINGAS N, WENDT M et al.: Mechanisms underlying nitrate-induced endothelial dysfunction: insight from experimental and clinical studies. Heart Failure Rev. (2002) 7:335–345.
   PubMedGoogle Scholar
• MONZEL T, LI H, MOLLNAU H et al.: Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. Circ. Res. (2000) 86:E7–E12.
   PubMedGoogle Scholar
• ABOU-MOHAMED G, KAESEMEYERWH, CALDWELL RB et al.: Role of L-arginine in the vascular actions and development of tolerance to nitroglycerin. Br. J. PbarmacoL (2000) 130:211–218.
   PubMedGoogle Scholar
• LAIGHT DW, CARRIER MJ, ANGGARD EE: Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy. Diabetes Metab. Res. Rev (1999) 15:274–282.
   PubMed Web of Science ®Google Scholar
• LAIGHT DW, CARRIER MJ, ANGGARD EE: Antioxidants, diabetes and endothelial dysfunction. Cardiovasc. Res. (2000) 47:457–464.
   PubMed Web of Science ®Google Scholar
• LIPINSKI B: Pathophysiology of oxidative stress in diabetes mellitus. I Diabetes Complications (2001) 15:203–210.
   PubMed Web of Science ®Google Scholar
• PENCKOFER S, SCHWERTZ D, FLORCZAK K: Oxidative stress and cardiovascular disease in Type 2 diabetes - the role of antioxidants and pro-oxidants. Cardiovasc. Nurs. (2002) 16:68–85.
   Google Scholar
• ROSEN P, NAWORTH PP, KING G et al.: The role of oxidative stress in the onset and progression of diabetes and its complications. Diabetes Metab. Res. Rev. (2001) 17:189–212.
   PubMed Web of Science ®Google Scholar
• WEST IC: Radicals and oxidative stress in diabetes. Diabet. Med (2000) 17:171–180.
   PubMed Web of Science ®Google Scholar
• ANFOSSI G, MULARONI EM, BURZACCA S et al.: Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care (1998) 21:121–126.
   PubMed Web of Science ®Google Scholar
• CHIRKOV YY, HOLMES AS, CHIRKOVA LP et al: Nitrate resistance in platelets from patients with stable angina pectoris. Circulation (1999) 100:129–134.
   PubMedGoogle Scholar
• MCVEIGH GE, BENNAN GM, HAYES R et al: Primary nitrate tolerance in diabetes mellitus. Diabetologia (1994) 37:115–117.
   PubMed Web of Science ®Google Scholar
• MCVEIGH GE, MORGAN DR, RIMBLE M et al.: Early vascular abnormalities and de novo nitrate tolerance in diabetes mellitus. Diabetes Obesity Metab. (2002) 4:336–341.
   PubMedGoogle Scholar
• GIUGLIANO D, MARFELLA R, VERRAZZO G et al: Abnormal rheologic effects of glyceryl trinitrate in patients with NIDDM and reversal by antioxidants. Ann. Intern. Med. (1995) 123:338–343.
   PubMedGoogle Scholar
• •This paper illustrates the notion of paradoxical clinical responses to organic nitrates as a result of established oxidant stress associated with diabetes
   Google Scholar
• MALMBERG K, RYDEN L: Myocardial infarction in patients with diabetes mellitus. Eur. Heart J. (1988) 9:259–264.
   PubMed Web of Science ®Google Scholar
• CANTRILL JA, D'EMANUELE A, DORNAN TL et al.: A survey of drug treatment and outcomes in diabetic patients with acute myocardial infarcts. J. Clin. Pbarm. Titer. (1995):207–213.
   Google Scholar
• YUSUF S, COLLINS R, MACMAHON S et al.: Effect of intravenous nitrates on mortality in acute myocardial infarction - an overview of randomised trials. Lancet (1988) 1:1088–1092.
   PubMed Web of Science ®Google Scholar
• HELD P: Effects of nitrates on mortality in acute myocardial infarction and in heart failure. Br. Clin. Pbarmacol. (1992) 34:25S–28S.
   Google Scholar
• MORRIS JL, COWAN JC: Nitrates in myocardial infarction - a current perspective. Can.j Cardiol. (1995) 11:5B–10B.
   Google Scholar
• NAKAMURA Y, MOSS AJ, BROWN MW et al: Long-term nitrate use may be deleterious in ischaemic heart disease - a study using the databases from two large-scale postinfarction studies. Am. Heart (1999) 138:577–585.
   PubMed Web of Science ®Google Scholar
• •This meta-analysis reveals adverse outcomes associated with organic nitrate therapy.
   Google Scholar
• KANAMASA K, HAYASHI T, KIMURA A et al.: Long-term, continuous treatment with both oral and transdermal nitrates increases cardiac events in healed myocardial infarction patients. Angiology (2002) 53:399–408.
   PubMed Web of Science ®Google Scholar
• •These observations suggest adverse outcomes associated with organic nitrate therapy.
   Google Scholar
• ISHIKAWA K, KANAMASA K, OGAWA I: Long-term nitrate treatment increases cardiac events in patients with healed myocardial infarction. fpn Circ. (1996) 60:779–788.
   Google Scholar
• •These observations suggest adverse outcomes associated with organic nitrate therapy.
   Google Scholar
• WEIGHTMAN WM, GIBBS NM, SHEMINANT MR et al.: Drug therapy before coronary artery surgery: nitrates are independent predictors of mortality and P-adrenergic blockers predict survival. Anesth. Analg. (1999) 88:286–291.
   PubMedGoogle Scholar
• LAIGHT DW: Therapeutic approaches to insulin resistance. Expert Opin. Titer. Patents (2000) 10:1703–1709.
   Web of Science ®Google Scholar
• EGAN BM, GREENE EL, GOODFRIEND TL: Insulin resistance and cardiovascular disease. Ant.J. Hypertens. (2001) 14:116S–125S.
   Google Scholar
• GROOP LC: Insulin resistance - the fundamental trigger of Type 2 diabetes. Diabetes Obesity Metab. (1999) 1:51–57.
   Google Scholar
• LAIGHT DW, DESAI KM, GOPAUL NK et al.: Pro-oxidant challenge in vivo provokes the onset of NIDDM in the insulin resistant obese Zucker rat. Br. J. Pbarmacol (1999) 128:269–271.
   PubMed Web of Science ®Google Scholar
• •This paper describes for the first time the progression to Type 2 diabetes of a pre-diabetic, insulin resistant state following experimental oxidant stress.
   Google Scholar
• LAIGHT DW, DESAI KM, ANGGARD EE et al.: Endothelial dysfunction accompanies a pro-oxidant, pro-diabetic challenge in the insulin resistant, obese Zucker rat in vivo. Eur. Pbarmacol. (2000) 402:95–99.
   PubMedGoogle Scholar
• WAY KJ, KATAI N, KING GL: Protein kinase C and the development of diabetic vascular complications. Diabet. Med (2001) 18:945–959.
   PubMed Web of Science ®Google Scholar
• LAIGHT DW: Nitric oxide therapy for cardiovascular disease. Expert Opin. Tiler. Patents (2001) 11:999–1005.
   Web of Science ®Google Scholar
• WARNER GT, PERRY CM: Ramipril: a review of its use in the prevention of cardiovascular outcomes. Drugs (2002) 62:1381–1405.
   PubMedGoogle Scholar
• LAIGHT DW: Therapeutic approaches to the management of dysmetabolic cardiovascular disease. Expert Opin. Tiler. Patents (2002) 12:615–620.
   Web of Science ®Google Scholar
• NORHAMMER A, TENERZ A, NILSSON G et al.: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus - a prospective study. Lancet (2002) 359:2140–2144.
   PubMedGoogle Scholar
• STASCH J-P, ALONSO-ALIJA C, APELER H et al.: Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41–8543 - M vitro studies. Br: J. Pbarmacol. (2002) 135:333–343.
   Google Scholar
• STASCHJ-P, SCHMIDT P, ALONSO-ALIJA C et al.: NO- and haem-independent activation of soluble guanylyl cyclase - molecular basis and cardiovascular implications of a new pharmacological principle. Br. Pbarmacol (2002) 136:773–783.
   PubMedGoogle Scholar
• PETRIE JR, UEDA S, WEBB DJ et al: Endothelial nitric oxide production and insulin sensitivity - a physiological link with importance for pathogenesis of cardiovascular disease. Circulation (1996) 93:1331–1333.
   PubMed Web of Science ®Google Scholar
• FRAME MD, FOX RJ, KIM D et a/.: Diminished arteriolar responses in nitrate tolerance involve ROS and angiotensin II. Ain. J. Physiol (2002) 282:H2377–H2385.
   Google Scholar
• FINK B, BASSENGE E: Association between vascular tolerance and platelet upregulation: comparison of non-intermittent administration of pentaerithrityltetranitrate and glyceryl trinitrate. Cardiovasc. Pharmacol. (2002) 40:890–897.
   PubMedGoogle Scholar
• OBERLE S, ABATE A, GROSSER N et al:Heme oxygenase-1 induction may explain the antioxidant profile of pentaerythrityl tetranitrate. Biochein. Biophys. Res. Commun. (2002) 290:1539–1544.
   PubMedGoogle Scholar